Insight Partners and Scale Venture Partners co-led a series C round for the GV-backed stroke detection software provider, taking its total funding to $150m.

Eli Lilly and Novartis Venture Fund participated in a round that will support the progress of Amphista's protein degradation drug candidates toward clinical trials.

The kidney healthcare provider boosted its total funding to more than $220m in a round led by Alphabet's CapitalG subsidiary.

Tencent and Gilead Sciences took part in a round that will fund clinical trials for three of Vaccitech's vaccine product candidates.

OSF Healthcare Ventures contributed to a $102m series D round for Inflammatix, a developer of diagnostics systems for detecting infections.

Novo co-led an $81.5m round for the gene therapy developer that included Sarepta Therapeutics, UCB Ventures, Takeda Ventures and Alexandria Venture Investments.

Novo Nordisk, Insulet and Mayo Clinic helped the diabetes monitoring technology provider push its overall funding past $100m.

This is the first in a series of quarterly publications for the Global Health Council looking at drug development, healthcare providers such as hospitals and digital health, payments and patient wellness. This first article looks at the implications of the disease treatments coming out of advanced research and artificial intelligence and the broader shift to digitalisation in healthcare. The next issue will focus on the providers of healthcare.

Binoy Bhansali was previously at Sandbox Industries, which manages $1.2bn across four funds for health insurer Blue Cross Blue Shield.

Q&A with Kurt Sheline, principal, Echo Health Ventures